β-Lactamase Characterization inEscherichia coliIsolates with Diminished Susceptibility or Resistance to Extended-Spectrum Cephalosporins Recovered from Sick Animals in Spain
- 1 June 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Microbial Drug Resistance
- Vol. 9 (2) , 201-209
- https://doi.org/10.1089/107662903765826804
Abstract
A total of 1439 Escherichia coli isolates from sick animals were received from the Spanish Network of Veterinary Antimicrobial Resistance Surveillance (VAV) from 1997 to 2001. Antimicrobial susceptibility tests were performed and diminished susceptibility to cefotaxime and ceftazidime was identified in 2.5% and 2.8% of the isolates, respectively. β-lactamase characterization was carried out in the group of 20 E. coli isolates with both characteristics. The MIC ranges of different β-lactams showed by these 20 isolates were as follows (in μg/ml): ampicillin (64->256), amoxicillin-clavulanic acid (4-64), ticarcillin (8->128), cefazolin (32->256), cefoxitin (4->128), cefotaxime (1-64), ceftazidime (2->64), ceftriaxone (0.5-64), imipenem (≤0.06-0.25), and aztreonam (2->32). TEM, SHV, CMY, and FOX β-lactamase genes were analyzed by PCR and sequencing. The β-lactamase genes detected were the following ones (number of isolates): blaTEM-1b(3), blaTEM-1a (1), blaTEM-30f (2), blaTEM-1b + blaCMY-2 and blaSHV-12 (1). Sequences of the promoter and/or attenuator region of the chromosomal ampC gene were studied in all the 20 isolates. Mutations at position -42 or -32 were detected in 16 isolates and these mutations were associated with the presence of a TEM type β-lactamase in 6 isolates. Besides, a high variety of plasmidic β-lactamases was detected including TEM-30 and CMY-2. To our knowledge, this is the first time that TEM-30 β-lactamase has been detected in E. coli isolates of animal origin.Keywords
This publication has 45 references indexed in Scilit:
- Plasmid-Determined AmpC-Type β-LactamasesAntimicrobial Agents and Chemotherapy, 2002
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Evidence for Transfer of CMY-2 AmpC β-Lactamase Plasmids between Escherichia coli and Salmonella Isolates from Food Animals and HumansAntimicrobial Agents and Chemotherapy, 2001
- Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alterationJournal of Antimicrobial Chemotherapy, 2000
- Animal and Human Multidrug-Resistant, Cephalosporin-Resistant Salmonella Isolates Expressing a Plasmid-Mediated CMY-2 AmpC β-LactamaseAntimicrobial Agents and Chemotherapy, 2000
- Antibiotic resistance monitoring: the Spanish programmeInternational Journal of Antimicrobial Agents, 2000
- Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum β-lactamase productionFEMS Microbiology Letters, 1999
- Nucleotide sequences of the genes coding for the TEM-like β-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2)FEMS Microbiology Letters, 1994
- Clinical isolates of Escherichia coli producing TRI β-lactamases: novel TEM-enzymes conferring resistance to β-lactamase inhibitorsJournal of Antimicrobial Chemotherapy, 1992
- The E. coli β-lactamase attenuator mediates growth rate-dependent regulationNature, 1981